Business growth

Bristol-Myers Squibb acquires Foribus. Bristol will receive only a portfolio of highly selective and powerful TGF-beta 1 and 3 inhibitors, which are key mediators of immunodepression and fibrosis. The most promising asset of the portfolio AVID200 has successfully passed the first phase of clinical trials. The rest of Foribus' assets will not be included in the perimeter of the deal, which is scheduled to be closed in Q4 2020.